GlassScriptPhysician profile
Amanda Dinsmore
NPI 1578806758
$1,545.85
in general payments reported to CMS, 2019-2025
22 companies · $580 in 2025
The $580 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $208 · 2022: $132 · 2023: $299 · 2024: $326 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,205.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $285.58 | 2021-2025 | Rocklatan, Tryptyr, Clareon |
| Tarsus Pharmaceuticals, INC. | $152.49 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $115.44 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $113.79 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $113.37 | 2022-2024 | Durysta, Lumigan, Vuity |
| Regeneron Healthcare Solutions, INC. | $96.91 | 2022-2024 | Eylea Hd |
| Dompe US, INC. | $73.53 | 2024-2025 | Oxervate |
| Astellas Pharma US INC | $63.39 | 2023-2024 | Izervay |
| Takeda Pharmaceuticals U.S.A., INC. | $62.89 | 2023-2025 | Entyvio |
| Sun Pharmaceutical Industries INC. | $62.42 | 2025 | |
| Novartis Pharmaceuticals Corporation | $61.37 | 2021-2023 | |
| Rayner Intraocular Lenses Limited | $45.98 | 2025 | Omidria, Rayone Spheric, Rayone Aspheric |
| Boston Scientific Corporation | $45.64 | 2025 | General - Hemostasis |
| Ocular Therapeutix, INC. | $43.72 | 2021-2025 | Dextenza |
| Thea Pharma INC. | $43.26 | 2025 | Iyuzeh |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $38.67 | 2021 | |
| Sight Sciences, INC. | $23.78 | 2023 | Omni Surgical System |
| Halozyme INC | $22.15 | 2024 | Hylenex Recombinant |
| Janssen Biotech, INC. | $21.60 | 2024 | Tremfya |
| Olympus America INC. | $21.47 | 2025 | Single Use Repositionable Clip |
| Ardelyx, INC. | $20.20 | 2025 | Ibsrela |
| Johnson & Johnson Surgical Vision, INC. | $18.20 | 2025 | Tecnis Iol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Dinsmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.